Maze Therapeutics Inc. (NASDAQ:MAZE) reported a fourth-quarter loss of $0.65 per share on Wednesday, while also announcing ...

Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...

Maze Therapeutics (MAZE) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its ...

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...

Investors had reservations over data from Maze for a drug that could compete with a candidate from Vertex in a ...

At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients ...

This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings ...